<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Farmaciya (Pharmacy)</journal-id><journal-title-group><journal-title xml:lang="en">Farmaciya (Pharmacy)</journal-title><trans-title-group xml:lang="ru"><trans-title>Фармация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0367-3014</issn><issn publication-format="electronic">2541-9218</issn><publisher><publisher-name xml:lang="en">Russkiy Vrach Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702805</article-id><article-id pub-id-type="doi">10.29296/25419218-2026-01-04</article-id><article-id pub-id-type="edn">qparod</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Technology of medicines</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Технология лекарственных средств</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Development of composition and manufacturing technology for soluble tablets with solid dispersion of tamsulosin hydrochloride</article-title><trans-title-group xml:lang="ru"><trans-title>Разработка состава и технологии получения растворимых таблеток с твердой дисперсией тамсулозина гидрохлорида</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6686-8166</contrib-id><contrib-id contrib-id-type="spin">2916-9833</contrib-id><name-alternatives><name xml:lang="en"><surname>Stantsov</surname><given-names>Maxim Igorevich</given-names></name><name xml:lang="ru"><surname>Станцов</surname><given-names>Максим Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>assistant professor at the Department of Analytical, Physical, and Colloid Chemistry of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>ассистент кафедры аналитической, физической и коллоидной химии, младший научный сотрудник НОИЦ «ФАРМА-ПРЕМИУМ» Института фармации им. А.П. Нелюбина</p></bio><email>stantsov_m_i@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8557-8829</contrib-id><contrib-id contrib-id-type="spin">1746-8595</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasnyuk</surname><given-names>Ivan Ivanovich</given-names></name><name xml:lang="ru"><surname>Краснюк</surname><given-names>Иван Иванович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Pharmaceutical Sciences, Professor, Head of the Department of Analytical, Physical and Colloidal Chemistry of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>доктор фармацевтических наук, профессор, заведующий кафедрой аналитической, физической и коллоидной химии Института фармации им. А.П. Нелюбина</p></bio><email>krasnyuk.79@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7242-2988</contrib-id><contrib-id contrib-id-type="spin">9865-8758</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasnyuk</surname><given-names>Ivan Ivanovich</given-names></name><name xml:lang="ru"><surname>Краснюк</surname><given-names>Иван Иванович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Pharmaceutical Sciences, Professor, Head of the Department of Pharmaceutical Technology of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>доктор фармацевтических наук, профессор, заведующий кафедрой фармацевтической технологии Института фармации им. А.П. Нелюбина</p></bio><email>krasnyuki@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-2691-1891</contrib-id><contrib-id contrib-id-type="spin">4996-3846</contrib-id><name-alternatives><name xml:lang="en"><surname>Tkachenko</surname><given-names>Daria Dmitrievna</given-names></name><name xml:lang="ru"><surname>Ткаченко</surname><given-names>Дарья Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Student, A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>студентка Института фармации им. А.П. Нелюбина</p></bio><email>tkachenko_d_d@student.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1620-699X</contrib-id><contrib-id contrib-id-type="spin">1422-1034</contrib-id><name-alternatives><name xml:lang="en"><surname>Oleneva</surname><given-names>Maria Sergeevna</given-names></name><name xml:lang="ru"><surname>Оленева</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant, Department of Analytical, Physical and Colloid Chemistry, A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>ассистент кафедры аналитической, физической и коллоидной химии Института фармации им. А.П. Нелюбина</p></bio><email>boldina_m_s@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9885-3727</contrib-id><contrib-id contrib-id-type="spin">1645-9092</contrib-id><name-alternatives><name xml:lang="en"><surname>Stepanova</surname><given-names>Olga Ivanovna</given-names></name><name xml:lang="ru"><surname>Степанова</surname><given-names>Ольга Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Pharmaceutical Sciences, associate professor at the Department of Pharmacology of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>кандидат фармацевтических наук, доцент кафедры фармакологии Института фармации им. А.П. Нелюбина</p></bio><email>o.i.nikulina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2968-2466</contrib-id><contrib-id contrib-id-type="spin">7523-5909</contrib-id><name-alternatives><name xml:lang="en"><surname>Bokov</surname><given-names>Dmitry Olegovich</given-names></name><name xml:lang="ru"><surname>Боков</surname><given-names>Дмитрий Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Pharmaceutical Sciences, Associate Professor, Department of Analytical, Physical, and Colloid Chemistry of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>кандидат фармацевтических наук, доцент кафедры аналитической, физической и коллоидной химии Института фармации им. А.П. Нелюбина</p></bio><email>bokov_d_o@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1614-1070</contrib-id><contrib-id contrib-id-type="spin">8479-0344</contrib-id><name-alternatives><name xml:lang="en"><surname>Grikh</surname><given-names>Victoria Vladimirovna</given-names></name><name xml:lang="ru"><surname>Грих</surname><given-names>Виктория Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Pharmaceutical Sciences, Associate Professor, Department of Analytical, Physical, and Colloid Chemistry of A.P. Nelyubin Institute of Pharmacy</p></bio><bio xml:lang="ru"><p>кандидат фармацевтических наук, доцент кафедры аналитической, физической и коллоидной химии Института фармации им. А.П. Нелюбина</p></bio><email>grikh_v_v_1@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-02-16" publication-format="electronic"><day>16</day><month>02</month><year>2026</year></pub-date><volume>75</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>26</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2026-02-16"><day>16</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-16"><day>16</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Russkiy Vrach Publishing House</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ИД "Русский врач"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Russkiy Vrach Publishing House</copyright-holder><copyright-holder xml:lang="ru">ИД "Русский врач"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2031-02-16"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/0367-3014/article/view/702805">https://journals.eco-vector.com/0367-3014/article/view/702805</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>The development of novel drug formulations remains a key challenge in modern pharmaceutical science. One promising direction is the design of soluble tablets that ensure rapid dissolution in water, high bioavailability of active ingredients, and ease of use. The development of effervescent tablets containing a solid dispersion of tamsulosin hydrochloride could significantly enhance the therapeutic efficacy of the drug by increasing its dissolution rate and improving the absorption of the active substance. This study aims to develop an optimal composition and manufacturing technology for effervescent tablets with a solid dispersion of tamsulosin hydrochloride, intended for the preparation of oral solutions <italic>(per os)</italic>.</p> <p><bold>Objective.</bold> The development of an optimal composition and efficient manufacturing technology for soluble tablets containing a solid dispersion of tamsulosin hydrochloride, intended for the preparation of peroral aqueous solutions. This includes the selection of the solid dispersion composition, development of the technological process, evaluation of the pharmaceutical characteristics of the obtained tablets, investigation of solubility and active substance release, as well as optimization of the stability of the resulting dosage form.</p> <p><bold>Material and methods.</bold> The composition includes the pharmaceutical substance tamsulosin hydrochloride, a polymer base – polyvinylpyrrolidone – 10000±2000 (pure grade), gas-forming agents: anhydrous sodium carbonate (pure grade), malic acid (analytical grade), tartaric acid (pure grade), citric acid (pure grade), a preservative component – sodium benzoate (pure grade), as well as solvents – 96% ethyl alcohol (pure grade), a structure-forming agent – mannitol, and purified water. The granulate production process was carried out by wet granulation in a fluidized bed using a Tofflon-HO Fluid Bed Dryer Mini DGC (China). Tableting was performed on a manual hydraulic testing press model “PRG” manufactured by VNIIR (Russia). A study was conducted on the relationship between compression pressure and such tablet quality indicators as disintegration time, friability, and crushing strength. The technological characteristics of the granulated mass and the finished effervescent tablets, including the establishment of expiration dates and determination of optimal storage conditions, were evaluated in accordance with the requirements of the State Pharmacopoeia of the Russian Federation XV edition.</p> <p><bold>Results.</bold> A composition of effervescent tablets containing a solid dispersion of tamsulosin hydrochloride as the active substance has been developed. The soluble tablets ensure the formation of a true solution of tamsulosin with a concentration of 0.0004% in 100 ml of water at a temperature of 20°C within less than 5 minutes. Validation of the method for the quantitative determination of tamsulosin hydrochloride content in the effervescent tablets has been conducted. Quality standards for physicochemical methods of testing the tablet composition have been established. Tests, including accelerated aging and storage under normal conditions, confirmed the stability of the developed effervescent tablet composition.</p> <p><bold>Conclusion. </bold>A technological composition of a fast-dissolving effervescent dosage form of tamsulosin hydrochloride based on a solid dispersion has been developed. The formulation is presented as soluble tablets ensuring rapid release of the active substance with enhanced bioavailability.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Проблема разработки новых лекарственных форм (ЛФ) остается ключевой задачей современной фармацевтической науки. Одним из перспективных направлений является разработка растворимых таблеток, обеспечивающих быстрое растворение в воде, высокую биодоступность активных компонентов и удобство применения. Разработка шипучих таблеток с твердой дисперсией тамсулозина гидрохлорида (ТГ) может значительно повысить терапевтическую эффективность препарата благодаря увеличению скорости растворения и улучшению абсорбции действующего вещества. Данное исследование направлено на разработку оптимального состава и технологии получения шипучих таблеток с твердой дисперсией ТГ, предназначенных для приготовления растворов для перорального применения <italic>(per os)</italic>.</p> <p><bold>Цель</bold> исследования. Разработка оптимального состава и эффективной технологии получения растворимых таблеток с твердой дисперсией ТГ для приготовления пероральных водных растворов, включающая подбор состава твердой дисперсии, разработку технологического процесса, оценку фармацевтических характеристик получаемых таблеток, исследование растворимости и высвобождения активного вещества, а также оптимизацию стабильности полученной ЛФ.</p> <p><bold>Материал и методы.</bold> Состав включает фармацевтическую субстанцию ТГ, полимерную основу – поливинилпирролидон – 10000±2000 (х.ч.), газообразующие агенты: карбонат натрия безводный (х.ч.), яблочную кислоту (ч.д.а.), винную кислоту (х.ч.), лимонную кислоту (х.ч.), консервирующий компонент – бензоат натрия (х.ч.), а также растворители – этиловый спирт 96% (х.ч.), структурообразующий агент- маннитол и очищенную воду. Процесс получения гранулята проводился методом влажного гранулирования в псевдоожиженном слое с использованием установки Tofflon-HO Fluid Bed Dryer Mini DGC (Китай). Прессование таблеток выполнялось на ручном гидравлическом испытательном прессе модели «ПРГ» производства ВНИР (Россия). Проведено исследование взаимосвязи между давлением прессования и такими показателями качества таблеток, как распадаемость, истираемость и прочность при раздавливании. Технологические характеристики гранулированной массы и готовых шипучих таблеток, включая установление сроков годности и определение оптимальных условий хранения, оценивались в соответствии с требованиями Государственной Фармакопеи РФ XV издания.</p> <p><bold>Результаты. </bold>Разработан состав шипучих таблеток, содержащий в качестве активного вещества твердую дисперсию ТГ. Растворимые таблетки обеспечивают образование истинного раствора ТГ с концентрацией 0,0004% в 100 мл воды при температуре 20°C в течение &lt; 5 мин. Проведена валидация метода количественного определения содержания ТГ в составе шипучих таблеток. Установлены нормативы качества для физико-химических методов исследования состава таблеток. Испытания, включающие тест ускоренного старения и хранение в нормальных условиях, подтвердили стабильность разработанного состава шипучих таблеток.</p> <p><bold>Заключение. </bold>Разработан технологический состав быстрорастворимой шипучей ЛФ ТГ на основе твердой дисперсии, представленной в виде растворимых таблеток, обеспечивающих быстрое высвобождение активного вещества с повышенной биодоступностью.</p></trans-abstract><kwd-group xml:lang="en"><kwd>tamsulosin hydrochloride</kwd><kwd>soluble tablets</kwd><kwd>fast-dissolving tablets</kwd><kwd>solid dispersions</kwd><kwd>polyvinylpyrrolidone</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тамсулозин гидрохлорид</kwd><kwd>растворимые таблетки</kwd><kwd>быстрорастворимые таблетки</kwd><kwd>твердые дисперсии</kwd><kwd>поливинилпирролидон</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Nashivochnikova N.A. Conscious approach to the choice of conservative therapy for BPH. RMJ. Medical Review. 2022; 6 (4): 187–94. DOI: 10.32364/2587-6821-2022-6-4-187-194.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Urolithiasis. Clinical Guidelines. Ministry of Health of Russia. 2022; 65. URL: https://cr.minzdrav.gov.ru/recomend/123 (accessed May 12, 2025).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Charalabidis A., Sfouni M., Bergström C., Macheras P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Int. J. Pharm. 2019; 566: 264–81. DOI: 10.1016/j.ijpharm.2019.05.041.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharmaceutical Research. 1995; 12 (3): 413–20. DOI: 10.1023/A:1016212804288.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Belyatskaya A.V., Krasnyuk I.I.(Jr), Krasnyuk I.I., Stepanova O.I., Abgaryan Zh.A., Kudinova T.P., Vorob’yov A.N., Nesterenko I.S. Study of the solubility of ketoprofen from solid dispersions with polyvinylpyrrolidone. Moscow University Chemistry Bulletin. 2019; 74 (2): 93–9. DOI: 10.3103/S0027131419020056.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Huang S., Mao C., Williams R.O. (3rd), Yang C.Y. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions. J. Pharm. Sci. 2016; 105 (12): 3549–61. DOI: 10.1016/j. xphs.2016.08.017</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Younis M.A. Solid Dispersion Technology, a Contemporary Overview on a well-Established Technique. Universal J. of Pharmaceutical Research. 2017; 2 (3): 15–9. DOI: 10.22270/ujpr.v2i3.RW1.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Singh N., Sarangi M.К. Solid Dispersion – a Novel Approach for Enhancement of Bioavailability of Poorly Soluble Drugs in Oral Drug Delivery System. J. Pharm. Sci. 2017; 3 (2): 1–8. DOI: 10.19080/GJPPS.2017.03.555608.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Stantsov M.I., Krasnyuk I.I. (Jr.), Krasnyuk I.I., Belyatskaya A.V., Stepanova O.I., Grikh V.V., Bakhrushina E.O., Bokov D.O. Influence of Solid Dispersions on the Solubility of Tamsulosin. Farmatsiya, 2025; 74 (2): 38–45. https://doi.org/10.29296/25419218-2025-02-05</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Krasnyuk I.I. (Jr.), Belyatskaya A.V., Krasnyuk I.I., Stepanova O.I., Ovsyannikova L.V., Grikh V.V., Allenova T.M., Odintsova E.B. Prospects for using solid polyvinylpyrrolidone dispersions in medicine and pharmacy. Farmatsiya, 2016; 6: 7–11.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Teodorescu M., Bercea M., Morariu S. Biomaterials of PVA and PVP in medical and pharmaceutical applications: рerspectives and challenges. Biotechnology Advances. 2019; 37: 109–31. DOI: 10.1016/j. biotechadv.2018.11.008.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ben Osman Y., Liavitskaya T., Vyazovkin S. Polyvinylpyrrolidone affects thermal stability of drugs in solid dispersions. Int. J. Pharm. 2018; 551 (1–2): 111–20. DOI: 10.1016/j.ijpharm.2018.09.020.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Elagina A.O., Belyatskaya A.V., Krasnyuk I.I. (Jr.), Krasnyuk I.I., Stepanova O.I., Fateeva T.V., Smolyarchuk E.A., Kozin S.V., Plakhotnaya O.N., Rastopchina O.V., Rau J.V. Development of nitrofuran derivative: composition and technology of effervescent tablets with solid dispersions. Pharmacy &amp; Pharmacology. 2022; 10 (1): 55–68. DOI: 10.19163/2307-9266-2022-10-1-55-68.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ipci K., Öktemer T., Birdane L. Effervescent tablets: a safe and practical delivery system for drug administration. ENT Updates. 2016; 6 (1): 46–50. DOI: 10.2399/jmu.2016001009</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Stepanova O.I., Belyatskaya A.V., Krasnyuk I.I. (Jr.), Korol L.A. Development of the composition and technology of instant furacilin formulations. Farmatsiya. 2015; 3: 36–9.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Trigubchak O.V., Groshovyi T.A. Study of pharmaco-technological properties of products Sorb-Cel® for creating of effervescent tablets based on acetylsalicylic acid. Nauchnye vedomosti. 2015; 219 (22): 191–200.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Saigal N., Baboota S., Ahuja A., Ali J. Fast-dissolving intra-oral drug delivery systems. Expert Opin. Ther. Patents. 2008; 8 (7): 769–81. DOI:10.2399/ jmu.2016001009.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>García E.R., Thalhauser S., Loscertales H.R. Current evidence in the stability of medicines in dose administration aids: implications for patient safety. Expert Opinion on Drug Delivery. 2018; 15 (6): 577–87. DOI: 10.1080/17425247.2018.1480610.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert Opin. Drug Deliv. 2011; 8 (11): 1521–9. DOI: 10.1517/17425247.2011.628311</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pramod K., Tahir M.A., Charoo N.A., Ansari S.H., Ali J. Pharmaceutical product development: A quality by design approach. Int. J. Pharm. Investig. 2016; 6 (3): 129–38. DOI: 10.4103/2230-973X.187350.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Elagina A.O., Belyatskaya A.V., Krasnyuk I.I. (Jr.), Krasnyuk I.I., Stepanova O.I., Fateeva T.V., Smolyarchuk E.A., Kozin S.V., Plakhotnaya O.N., Rastopchina O.V., Rau J.V. Development of nitrofuran derivative: composition and technology of effervescent tablets with solid dispersions. Pharmacy &amp; Pharmacology. 2022; 10 (1): 55–68. DOI: 10.19163/2307-9266-2022-10-1-55-68.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Belyatskaya A.V. The specific features of technology for manufacturing freely soluble (effervescent) tablets. Farmatsiya. 2008; 3: 21–2.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Beliatskaya A.V., Krasnyuk I.I., Elagina A.O., Kashlikova I.M., Stepanova O.I., Kuzmenko A.N., Iskenderova S.G., Kannieva D.R., Vorob’yov A.N. Study of the solubility of furazolidone from solid dispersions with polyvinylpyrrolidone. Moscow University Chemistry Bulletin. 2020; 75: 43–6. DOI: 10.3103/S0027131420010046</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Nikolaeva L.L., Gulyakin I.D., Oborotova N.A., Bunatyan N.D. Analysis of polyvinylpyrrolidone in dosage forms. Pharmacy &amp; Pharmacology. 2016; 4 (2): 88–94. DOI: 10.19163/2307-9266-2016-4-2(15)-88-94.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Setkina S.B., Khishova O.M. Biopharmaceutical aspects of drug technology and methods of bioavailability modification. Bulletin of the Vitebsk State Medical University. 2014; 13 (4): 162–72.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chatzidopavlaki P., Triantafyllopoulou E., Pippa N., Valsami G., Dallas P.P. Recent advances in the technology of effervescent tablets: lessons learned and future perspectives. RSC Pharmaceutics. 2025; 2: 8–18.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Valeeva E.R., Lebedeva Yu.E., Kozlova Zh.M. Influence of gas-forming component quantity and compacting pressure on solubility of effervescent naproxen tablets. Mezhdunarodnyi nauchno-issledovatel'skii zhurnal. 2017; 7–2: 105–8.</mixed-citation></ref></ref-list></back></article>
